logo-loader
LSE:RENE FRA:RQE1

ReNeuron Group PLC

 Receive alerts
Market:
LSE
Market Cap:
£45.04 m
Price
141.50 GBX
Change
-1.74%
52 weeks high
297.50
52 weeks low
71.00
07.55

Director Interviews

In brief

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

ReNeuron encouraged by progress in stroke and RP treatments
dna strand

Snapshot

  • Developer of stem cell technologies
  • Has two clinical stage technologies
  • Stroke treatment in Phase IIb trials
Open Deep dive

Latest news

ReNeuron treatment for degenerative eye condition “meaningful effect” for...

4 days, 23 hours ago

Proactive news headlines: BATM Advanced Communications, Blue Star Capital,...

1 week, 1 day ago

ReNeuron Group agrees gene silencing collaboration with “major biotechnology...

1 week, 2 days ago

Proactive news headlines: Pelatro, Panther Metals, ReNeuron Group, Metal...

2 weeks, 2 days ago

ReNeuron to focus on retinal disease and exosome-based technology programmes

2 weeks, 3 days ago

ReNeuron Group's CTX therapy shows early promise in treating Huntington's...

on 7/5/20

ReNeuron jumps as it agrees research deal with unnamed “major pharmaceutical...

on 7/4/20

ReNeuron assessing potential of emerging cell technology in the coronavirus...

on 3/4/20

Interviews

ReNeuron Group PLC - ReNeuron's Michael Hunt explains new emphasis on its retinal and exosome technology programmes Health ReNeuron's Michael Hunt explains new emphasis on its retinal and exosome technology programmes
2 weeks, 2 days ago
ReNeuron Group PLC - ReNeuron Group PLC: Proactive One2One Virtual Event Health ReNeuron Group PLC: Proactive One2One Virtual Event
2 weeks, 6 days ago
ReNeuron Group PLC - ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating Huntington's disease Health ReNeuron's Michael Hunt talks new potential for its CTX therapy in treating Huntington's disease
on 11/5/20
ReNeuron Group PLC - ReNeuron looking at applications of its own technology to deliver virus vaccine Health ReNeuron looking at applications of its own technology to deliver virus vaccine
on 6/4/20
View all